ClinicalTrials.gg
RecruitingNCT06735599Updated Sep 2, 2026

Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure

An interventional study of Wild Blueberry and Placebo in Hypertension (Without Type 2 Diabetes Mellitus), High Blood Pressure and Male, sponsored by Georgia State University. Recruiting at 1 site in United States. Open to participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Georgia State University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
All
01

Study summary

The purpose of the study is to determine the effectiveness of wild blueberries on cardiovascular health, cognitive function, and gut microbiota composition in non-Hispanic Black and White adults with elevated blood pressure.

Read the detailed description

Hypertension (HTN), or high blood pressure (BP) is a major modifiable risk factor for heart disease, the leading cause of death worldwide. In the U.S., 121.5 million adults have high BP and only 25% have their BP under control. The 2022 Heart Disease and Stroke Statistics indicated that the incidence of high BP was higher among non-Hispanic Black (NHB) compared to non-Hispanic White (NHW) adults. Berries are rich in fiber and phytochemicals and have several health benefits. A 14-year follow-up of the Nurses' Health Study I and II and the Health Professional Follow-Up Study revealed a significant reduction in the risk of HTN (8%) among individuals in the highest quintile of anthocyanin intake compared to the lowest quintile. Blueberries are rich in fiber and phytochemicals that may be responsible for their health benefits. Studies have shown that daily blueberry consumption improves heart, cognitive, and intestinal health in different populations. Yet, a comprehensive study exploring and comparing the effectiveness of wild blueberries for cardiovascular, intestinal, and cognitive function parameters and their association in NHB and NHW adults with high BP has not been conducted to date.

Thus, the overall objective of this timely study is to determine and compare the effectiveness of a freeze-dried wild blueberry intervention on cardiovascular and gut health in NHB and NHW adults with high BP and assess whether these health benefits are associated with improvements in memory and other important thinking abilities for productivity and quality of life.

Therefore, this 6 - month randomized, placebo-controlled crossover clinical trial aims to assess whether daily consumption of 22 g of freeze-dried wild blueberry powder improves gut, cardiovascular, and cognitive function in NHB and NHW adults with elevated blood pressure and stage 1 hypertension. Investigators hypothesize that daily consumption of wild blueberries will improve cardiovascular parameters, gut dysbiosis, and cognitive function. To test these hypotheses, the following specific aims are proposed. To investigate whether daily consumption of 22 g of freeze-dried wild blueberry powder:

  • Reduces BP, improves endothelial function, arterial stiffness, and microcirculation.
  • Favorably modulates gut microbiota composition.
  • Improves cognitive function (verbal memory and executive functions [inhibition, working memory, cognitive flexibility]).
  • Improves serum markers of oxidative stress and inflammation.

Additionally, investigators will also explore whether changes in the gut microbiota are associated with changes in cardiometabolic and cognitive function outcomes and whether changes in cardiometabolic outcomes are associated with changes in cognitive function parameters globally and within each race.

02

Conditions studied

  • Hypertension (Without Type 2 Diabetes Mellitus)
  • High Blood Pressure
  • Male
  • Female
  • Adult
  • Cognition
  • Endothelial Function (Reactive Hyperemia)
  • Oxidative Stress
  • Diet
  • Overweight
  • Body Composition Measurement
  • Gut Microbiome
  • Arterial Stiffness
  • Caucasian Whites
  • Inflammation
  • Microvascular Function

Keywords

  • Blueberries
  • Hypertension
  • Overweight
  • High Blood Pressure
  • Endothelial Function
  • Cognitive Function
  • Dietary intervention
  • functional foods
  • gut microbiota
  • arterial stiffness
  • microvascular function
03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's planned enrollment of 40 is below the median of 100 across 4,575 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Georgia State University is the lead sponsor of 56 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals 45-65 years of age
  • Diagnosis of elevated blood pressure or stage 1 hypertension (systolic blood pressure = 120-139 mmHg and/or diastolic blood pressure = 80-89 mmHg) for at least 6 months
  • 25-35 kg/m2 via anthropometric measurements.
  • Ability to give consent

Exclusion criteria

Exclusion Criteria:

  • Allergies to berries
  • Use of one hypertensive drug for less than three months
  • Use of more than one anti-hypertensive or statin drug, insulin, antibiotics, and anti-inflammatory drugs, active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological disorders or severe head injury
  • Smoking
  • Alcohol consumption (>2 drinks/day)
  • Consuming antioxidant, probiotic, and prebiotic supplements
  • Pregnant or lactating
  • Participating in a weight loss program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Wild Blueberry

    22 g of freeze-dried wild blueberry freeze-dried powder per day

    Dietary Supplement: Wild Blueberry

  • Placebo comparator
    Placebo

    22 g of freeze-dried macronutrient-matched placebo powder per day

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementWild Blueberry

    Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 8 weeks

  • Dietary supplementPlacebo

    Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 8 weeks

06

What researchers measure

Primary outcomes

  1. Ambulatory Blood Pressure

    Assessment of whole-day ambulatory blood pressure during daytime and nighttime periods.

    Time frame: Baseline, 4 weeks, and 8 weeks

  2. Pulse Wave Velocity

    Arterial Stiffness will be measured by pulse wave velocity using SphygmCor

    Time frame: Baseline, 4 weeks, and 8 weeks

Secondary outcomes

  1. Reactive Hyperemia Index

    Assessment of endothelial function in response to increased shear stress using EndoPAT2000

    Time frame: Baseline, 4 weeks, and 8 weeks

  2. Gut Microbiota Composition

    Analysis of stool sample for determination of absolute levels of bacteria and relative species composition

    Time frame: Baseline, 4 weeks, and 8 weeks

  3. Global Cognitive Ability

    Measured using NIH Toolbox Picture Vocabulary and Oral Reading Recognition test

    Time frame: Screening

  4. Performance Validity

    Assessed using Rey 15

    Time frame: Baseline, 4 weeks, and 8 weeks

  5. Verbal Memory & Recognition

    Measured using Rey Auditory Verbal Learning Test with appropriate alternate forms

    Time frame: Baseline, 4 weeks, and 8 weeks

  6. Cognitive Inhibition

    Assessed using Delis-Kaplan Executive Function System Trails and Verbal Fluency Switching

    Time frame: Baseline, 4 weeks, and 8 weeks

  7. Working Memory

    Measured using Digit Span and NIH Toolbox List Sorting

    Time frame: Baseline, 4 weeks, and 8 weeks

  8. Processing Speed

    Measured using NIH Toolbox Pattern Comparison and Oral Symbol Digit tests

    Time frame: Baseline, 4 weeks, and 8 weeks

  9. Associative Memory

    Measured using NIH Toolbox Face Name Associative Memory Exam and Face Name Associative Memory Exam Delay tests

    Time frame: Baseline, 4 weeks, and 8 weeks

  10. Attention

    Assessed using Wechsler Adult Intelligence Scale - IV and Rey Auditory Verbal Learning Test Trial 1.

    Time frame: Baseline, 4 weeks, and 8 weeks

  11. Problem-Solving

    Assessed using NIH Toolbox Visual Reasoning

    Time frame: Baseline, 4 weeks, and 8 weeks

Other outcomes

  1. Percent Maximal Microvascular Blood Flow

    Micro-vessel blood flow in response to local heating stimulus will be assessed using a Laser Doppler

    Time frame: Baseline, 4 weeks, and 8 weeks

  2. Circulating Markers of Inflammation and Oxidative Stress

    Measurement of concentrations of circulating markers of inflammation such as CRP and oxidative stress such as TBARS in blood plasma and serum samples.

    Time frame: Baseline, 4 weeks, and 8 weeks

  3. Urinary Polyphenolic Metabolites

    24-hour urine collection samples will be assessed for polyphenol metabolites

    Time frame: Baseline, 4 weeks, and 8 weeks

  4. Body Fat

    DEXA will be used to assess body fat mass

    Time frame: Baseline, 4 weeks, 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Georgia State University
    Atlanta, Georgia 30303, United States
    Recruiting
    • Rafaela Feresin, PhD · Contactberries@gsu.edu · 404-413-1233
    • Rafaela G Feresin, PhD · Principal investigator
    • Andrew Gerwitz, PhD · Sub investigator
    • Tricia Z King, PhD · Sub investigator
    • Brett J Wong, PhD · Sub investigator
    • Elizabeth L Tighe, PhD · Sub investigator
08

References and documents

Publications

  • Krikorian R, Skelton MR, Summer SS, Shidler MD, Sullivan PG. Blueberry Supplementation in Midlife for Dementia Risk Reduction. Nutrients. 2022 Apr 13;14(8):1619. doi: 10.3390/nu14081619. PubMed 35458181 ↗
  • Johnson SA, Figueroa A, Navaei N, Wong A, Kalfon R, Ormsbee LT, Feresin RG, Elam ML, Hooshmand S, Payton ME, Arjmandi BH. Daily blueberry consumption improves blood pressure and arterial stiffness in postmenopausal women with pre- and stage 1-hypertension: a randomized, double-blind, placebo-controlled clinical trial. J Acad Nutr Diet. 2015 Mar;115(3):369-377. doi: 10.1016/j.jand.2014.11.001. Epub 2015 Jan 8. PubMed 25578927 ↗
  • Cassidy A, O'Reilly EJ, Kay C, Sampson L, Franz M, Forman JP, Curhan G, Rimm EB. Habitual intake of flavonoid subclasses and incident hypertension in adults. Am J Clin Nutr. 2011 Feb;93(2):338-47. doi: 10.3945/ajcn.110.006783. Epub 2010 Nov 24. PubMed 21106916 ↗
  • Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM, Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME, Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroeder EB, Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang NY, Yaffe K, Martin SS. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022 Feb 22;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052. Epub 2022 Jan 26. PubMed 35078371 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jan 2027, 27 months after the start.

Of 1,403 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 27 months is above that.

Counting every sponsor, half of 1,498 studies reached it within 23 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Dec 16, 2024
StartActual
Sep 17, 2024
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06735599
Lead sponsor
Georgia State University
Responsible party
Rafaela G. Feresin (Associate Professor, Georgia State University) — Principal investigator
First posted
Dec 16, 2024
Start date
Sep 17, 2024
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Rafaela G Feresin, PhD
Contact
berries@gsu.edu
404-413-1233
Rafaela G Feresin, PhD
principal investigator · Georgia State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion